DICER1 Syndrome

Authors: Věra Hořínová 1,2;  Klára Drábová 3,4;  Hana Nosková 5;  Viera Bajčiová 4;  Jana Šoukalová 3;  Leona Černá 6;  Věra Hůrková 7;  Ondřej Slabý 8;  Jaroslav Štěrba 4
Authors‘ workplace: Ambulance lékařské genetiky, Nemocnice Jihlava 1;  Reprofit, Brno 2;  Oddělení lékařské genetiky, FN Brno 3;  Klinika dětské onkologie, FN Brno 4;  CEITEC – Středoevropský technologický institut, Masarykova univerzita a FN Brno 5;  Gennet, Praha 6;  PREDIKO, Zlín 7;  Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno 8
Published in: Klin Onkol 2019; 32(Supplementum2): 123-127
Category: Case Report
doi: 10.14735/amko2019S123


DICER1 syndrome is an inherited disorder that increases the risk of different types of malignant and benign tumors. The syndrome is caused by mutations in the DICER1 gene, which is located on the long arm of chromosome 14, region q32.13. Patients with DICER1 syndrome commonly develop pleuropulmonary blastoma (PPB), multinodular goiter, ovarian Sertoli–Leydig cell tumors, and/or other types of tumors. In approximately 35% of families with children manifesting PPB, further (and rather rare) malignancies may be observed, including cystic nephroma, nodular dysplasia of the thyroid gland, medulloepithelioma of the iris, embryonal rhabdomyosarcoma botryoid type, nasal epithelial hamartoma, pituitary blastoma, and/or pineoblastoma. Large studies report a high variability of tumors associated with DICER1. DICER1 syndrome, which is associated with an inherited predisposition to tumors, is inherited in an autosomal dominant pattern. Symptoms of DICER1 syndrome may vary, even within families. Preventive screening of carriers with causative mutations is complicated. Follow-up is undertaken as recommended by the 2016 International PPB Register.

This work was supported by grant of Ministry of Health of the Czech Republic AZV 16-3329A.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 4. 6. 2019

Accepted: 6. 6. 2019


genetic testing – hereditary cancer syndromes – DICER1 – pleuropulmonary blastoma – cystic nephroma


1. Slade I, Bacchelli CH, Davies H et al. DICER1 syndrome: clarifying the diagnosis, clinical futures and management implications of a pleiotropic tumor predisposition syndrome. J Med Genet 2011; 48 (4): 273–278. doi: 10.1136/jmg.2010.083790.

2. Schultz KA, Williams GM, Kamihara J et al. DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies. Clin Cancer Res 2018; 24 (10): 2251–2261. doi: 10.1158/1078-0432.CCR-17-3089.

3. Kim J, Field A, Schultz KA et al. The prevalence of DICER1 pathogenic variation in population databases. Int J Cancer 2017; 141 (10): 2030–2036. doi: 10.1002/ijc.30907.

4. Stewart DR, Best AF, Williams GM et al. Neoplasm risk among individuals with a pathogenic germline variant in DICER1. J Clin Oncol 2019; 37 (8): 668–676. doi: 10.1200/JCO.2018.78.4678.

5. Hill DA, Dehner LP. A cautionary note about congenital cystic adenomatoid malformation (CCAM) type 4. Am J Surg Pathol 2004; 28 (4): 554–555.

6. Hill DA, Ivanovich J, Priest JR et al. Germline DICER1 mutations in familial pleuropulmonary blastoma. Science 2009; 325 (5943): 965. doi: 10.1126/science.1174334.

7. Priest JR, Watterson J, Strong L. Pleuropulmonary blastoma: a marker for familial disease. J Pediatr 1996; 128 (2): 220–224.

8. Doros L, Schultz KA, Stewart DR et al. DICER1-related disorders: genereviews. [online]. Available from: http: //www.ncbi.nlm.nih.gov/books/NBK196157/.

9. Schultz KA, Rednam SP, Kamihara J et al. PTEN, DICER1, FH, and their associated tumor susceptibility syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017; 23 (12) : e76–e82. doi: 10.1158/ 1078-0432.CCR-17-0629.

10. The International Pleuropulmonary Blastoma/DICER1 Registry. [online]. Available from: www.PPBregistry.org.

11. European Cooperative Study Group for Pediatric Rare Tumors. [online]. Available from: www.raretumors-children.eu.

Paediatric clinical oncology Surgery Clinical oncology

Article was published in

Clinical Oncology

Issue Supplementum2

2019 Issue Supplementum2

Most read in this issue

This topic is also in:

Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account